ZIOPHARM Oncology, Inc., a biopharmaceutical company, develops and commercializes a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidates that are related to cancer therapeutics, which are already on the market or in development. The company’s product candidates include darinaparsin (ZIO-101), palifosfamide (ZIO-201), and indibulin (ZIO-301). The ZIO-101, an organic arsenic compound, is in Phase II trial in patients with liver cancer, leukemia/lymphoma, and myeloma, as well as in Phase I trial for oral administration. The ZIO-201, a proprietary active metabolite of the pro-drug ifosfamide, is in Phase II trail in patients with advanced sarcoma, as well as Phase I/II trail in patients with sarcoma combination. The ZIO-301, an anti-cancer agent that targets mitosis like the taxanes, is in a Phase I trial. The company was founded in 2003 and is headquartered in New York, New York.